Can't introduce Bt cotton tech in India due to royalty issues: Bayer AG

Image
Press Trust of India Monheim
Last Updated : Sep 18 2018 | 6:55 PM IST

German chemical and pharma major Bayer AG, which has acquired biotech company Monsanto, Tuesday said it cannot introduce new Bt cotton seed technology in India as it has become difficult to make money in the south Asian nation because of royalty issues.

In June this year, Bayer completed the USD 63 billion mega-deal to acquire US-based Monsanto to create the world's biggest agro-chemical and seed company. The acquisition of Monsanto has been completed globally but it is still in process in India.

Monsanto has been selling genetically modified (GM) cotton seeds in India for more than a decade through its joint venture Mahyco Monsanto Biotech that has sub-licensed Bt cotton seed technology to various domestic seed companies.

However, the company is now involved in a legal case where it has appealed against the Indian government's decision to fix cotton price along with trait value (royalty) under the Cotton Seed Price Control Order.

Separately, it is fighting a legal case with Indian firm Nuziveedu Seeds over patent right of its technology.

Asked about Monsanto's threat of not introducing any new technology in India due to royalty issues, Bob Reiter, Global head of R&D, Crop Science Division of Bayer, emphasised that the company needs to be compensated for investment made in R&D to come up with innovative products.

"The issue around Bt cotton in reality is that as a company we cannot serve a market if that market does not pay for the invention we are trying to bring in. The challenge in India has been that the government has stepped into, I would say, a conflict that started between licensees and become more complex," Reiter said.

Reiter was previously the Global Vice President of R&D and Integration Strategy at Monsanto.

"The reality is that now nobody can make any money in the trait market and even make less money in seed market in India, which in my opinion is not suitable for the market and customers as well," he said at Bayer's annual event on 'Future of Farming Dialogue' here.

He further said: "It has forced a situation where if this is the way we are going to be compensated for technology and innovation, we just fundamentally cannot do it.

This, he said was a "great disappointment."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 18 2018 | 6:55 PM IST

Next Story